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 Abstract 
Objectives: The purpose of this study was to investigate bone morphogenetic protein 
(BMP)-2 expression following implantation of a statin and recombinant human BMP-2 
(rhBMP-2), and to compare the bone regeneration capability of these substances in the 
rabbit nasal bone using immunohistological methods.  
Study design: Twelve adult male Japanese white rabbits (n = 12, age: 12–16 weeks, 
weight: 2.5–3.0 kg) were divided into three experimental groups and one control group.  
A total of 48 bone defects, four per rabbit, were created in the nasal bone while 
preserving the nasal membrane. In the experimental groups, one group was implanted 
with 10 mg statin dissolved in 0.2 ml water with an atelocollagen sponge (ACS), the 
second group was implanted with 5 μg rhBMP-2 with an ACS, and in the third group 
only the ACS was implanted.  No material was implanted in the control group.  
Animals were killed at 1-, 2-, and 4- weeks postoperatively.  The parts that had been 
operated on were removed and prepared for histological assessment.  The expression 
of BMP-2 was evaluated using immunohistochemistry, and double-immunostaining for 
BMP-2 and Ki67 was observed by fluorescent microscopy. 
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Results: No significant differences were observed between the statin/ACS group and 
rhBMP-2/ACS group at 1, 2, and 4 weeks postoperatively. The number of cells which 
stained positively for BMP-2 increased significantly in both of the implanted groups 
when the control group (P<0.0001). The positive fluorescent double- immunostaining 
for BMP-2 and Ki 67 was similar in both implanted groups. 
Conclusion: This study suggests that stain/ACS implants showed BMP-2 expression 









Autologous bone is the current gold standard graft material for the treatment of 
skeletal defects and fracture repair.  However, the need for a second surgical site and 
the limited supply of bone available has led to the development of various alternative 
materials to autologous bone grafts.  
Statins are specific, competitive inhibitors of 3-hydroxy-2-methyl-glutaryl 
coenzyme A (HMG CoA) reductase, and include naturally occurring lovastatin, 
chemically modified simvastatin and pravastatin1-3 and the synthetically derived 
atorvastatin, fluvastatin, and cerivastatin.  All of these agents are widely used to lower 
cholesterol, and they provide an important and effective approach towards the treatment 
of hyperlipidemia and arteriosclerosis4.  However, statins also appear to modulate bone 
formation, inflammation, and angiogenesis.  The suggestion that statins can increase 
bone formation has provided an exciting new direction for research as well as providing 
a greater understanding of the biological importance of cholesterol synthetic pathways. 
Simvastatin, mavastatin, and lovastatin have been shown to stimulate bone formation5. 
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However, there are no reports on pravastatin inducing bone formation in vivo.  
Bone morphogenetic proteins (BMPs) are active bone-inducing factors that act 
on immature mesenchymal cells, including osteoblasts, resulting in osteogenesis.  So 
far, several types of BMPs have been isolated using molecular cloning, and recombinant 
BMP molecules have been synthesized6.  Recombinant human BMP-2 (rhBMP-2) is a 
molecule that powerfully induces bone generation in vivo7.  However, to optimize 
delivery at the bone repair site, rhBMP-2 requires a suitable carrier.  Kusumoto et al.8 
reported that the atelopeptide type 1 collagen sponge is a useful carrier for 
osteoinduction by rhBMP-2.   
To date, no experiments have been reported that have investigated the 
expression of BMP-2 induced by pravastatin during bone regeneration.  The purpose 
of this study was to evaluate the bone regeneration process histologically and 
immunohistochemically using pravastatin or rhBMP-2 with atelocollagen sponge (ACS) 
implant materials in rabbit nasal bones, and to compare the bone regenerative capability 




Materials and Methods 
 
The experimental protocol was approved by the Institutional Committee for 
Animal Care, Kanazawa University. 
 
Experimental animals 
Twelve male Japanese white rabbits (12-16 weeks, 2.5-3.0 kg) were used in 
this experiment. They were divided into four groups – three experimental and one 




 The whole procedure was performed under sterile conditions. First, the animals 
were anesthetized with sodium pentobarbital (25 mg/kg), injected into the lateral ear vein. 
Then the hair in the nasal bone was shaved. After that, 1.8 ml of 2% lidocaine containing 
1:80,000 epinephrine was administered into the operating site. Both the nasal bone and 
nasoincisinal suture line were exposed via a perpendicular incision. With the use of a 
fissure bur, four nasal bone windows were outlined. A surgical defect (5mm in diameter) 
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was made with a fissure bur using continuous saline irrigation. Great care was taken to 
avoid injury to the preserving nasal membrane. Four bone defects ⎯three experimental 
and one a control⎯were created in each animal (Fig 1). The bone defect of this study is 
defined as a critical sized defect. This size has been reported to prevent spontaneous 
healing during animal’s lifetime.9
 
Implant materials 
 The implant materials were a statin (Mevalotin®, pravastatin sodium, Sankyo 
Co. Tokyo, Japan), ACS (Teruplug®, Terumo Co. Tokyo, Japan), and rhBMP-2 with 
ACS (Teruplug®, Terumo Co. Tokyo, Japan). Forty eight bone defects were created at 
the nasal bones of Japanese rabbits, while preserving the nasal membrane. In the 
experimental group, defects were implanted with 10mg statin (Mevalotin®, pravastatin 
sodium, Sankyo Co. Tokyo, Japan), dissolved with 0.2 ml water and implanted into 
approximately 60 mm3 (diameter 5 mm, thickness 3mm) ACS (Teruplug®, Terumo Co. 
Tokyo, Japan). Rh-BMP-2 with approximately 60 mm3 (diameter 5 mm, thickness 
3mm) ACS and approximately 60 mm3 (diameter 5 mm, thickness 3mm) ACS alone 
were implanted. The rhBMP-2 was provided by Yamanouchi (Astellas) Pharmaceutical 
Co, Ltd, Japan. The rhBMP-2 was suspended in a buffer (pH 4.5) consisting of 5 mM 
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L-glutamic acid, 2.5% glycine, 0.5% sucrose, and 0.01% Tween 80 (Difco Laboratories, 
Detroit, MI, USA). It was kept at a temperature of –80ºC until needed, at which time it 
was thawed at room temperature. The ACS was cut into approximately 60 mm3 (diameter 
5 mm, thickness 3mm) blocks. In the rhBMP-2 implants, 5μg rh-BMP-2 was absorbed 
with approximately 60 mm3 (diameter 5 mm, thickness 3mm) of ACS. This mixture was 
lyophilized before being implanted into the animals along the nasal bone. No material 
was implanted into the control group. 
. 
Immunohistochemistry examination 
 The rabbits were sacrificed at 1, 2 and 4 weeks postoperatively and the 
specimens were fixed with 10% buffered formaldehyde overnight at 4°C, and 
demineralized with 14% EDTA for 4 weeks. The specimens were dehydrated with a 
graded ethanol series, cleared with xylene and embedded in paraffin. Five-mm sections 
were cut and mounted on gelatin-coated glass slides. Firstly, the prepared sections were 
treated with hematoxyline and eosin (HE). Then they were treated successively with 
0.3% tween 20 in PBS for one hour for cell permeabilization, and then with 0.3% 
hydrogen peroxide in methanol for 10 min to inhibit intrinsic peroxides activity. They 
were then incubated overnight at room temperature with antibody BMP2 at 1: 100 
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dilutions in PBS. After washing with PBS, the sites of the immunoreactions were 
visualized by incubating the sections successively with biotinylated anti rabbit Ig G 
antibody at 1: 200 dilutions for 1hr, horseradish peroxides –conjugated streptavidin 
(Dako) at 1: 300 dilutions for 1 hour, and 0.01% diaminobenzidine tetrahydrochloride in 
the presence of 0.02% hydrogen peroxide in 50 mM Tris-HCL, pH 7.5 for 10 min.. The 
sections counterstained with hematoxylin were observed under on Olympus BX 50 
microscope (Olympus; Tokyo, Japan). The sections were then dehydrated in alcohol and 
mounted for light microscopy to count the number of positively stained active cells in the 
regeneration site. The observation area was determined by the center of the bone defect 
area (material implanted area) (Fig.2).  The number of stained cells per 1000 cells in 
this area was counted by hand using high magnification photomicrograph (×100). 
 
Fluorescent double- immunostaining for BMP-2 and Ki 67 was performed. The sections 
were incubated with the mixture of rabbit BMP-2 antibody (1:500 dilutions) and Ki-67 
(1:250 dilutions) in PBS overnight at 4°c.  After washing with PBS, the sections were 
incubated with a mixture of Alexa Fluor 594-labeled anti-rabbit IgG and Alexa Flour 
488-labeled anti-mouse IgG for 1 hr. They were then mounted in glycerol and subjected 
to examination with a fluorescent microscope (Olympus BX50/BX-FLA) first, using 
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green emission for Alexa Fluor 594 and then red emission for Alexa Fluor 488. 
 
Statistical Analysis  
Data of all the implanted materials were statistically analyzed with Stat View 4.5 
(ABACUS Concepts, Inc., Berkeley, CA, USA). Differences between groups were 
analyzed by non-paired comparison using Scheffe’s F test. Time-dependent changes 
were examined by analysis of variance (ANOVA). Differences were considered 
significant at P< 0.05. 
 
Results 
Healing progressed uneventfully in all the animals and no postoperative 
complications were noted during the 4 week observation period. After resting for 3-6 




No findings suggestive of inflammation were observed at 1 week in any 
specimen. At 2 weeks, the operated area was partially covered with fibrous tissue in the 
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statin/ACS and rhBMP-2/ACS groups. At 4 weeks, the operated area was not restored 
completely and residual ACS was still visible. However, osteoblasts and fibroblasts in 
the implanted groups were found under microscopic observation using hematoxylin 
staining. But there were no changes in all the periods of the control groups. 
. 
Statin /ACS treated with BMP-2 antibody  
 At 1 week, there were many positive immunostained cells (Fig. 3A).  At 2 weeks, 
these positive cells were slightly decreased (Fig. 3 B) whereas the positive stained cells 
markedly decreased and reached the minimal level at4 weeks (Fig. 3C) 
 
RhBMP-2/ACS treated with BMP-2 antibody  
The positive immunostaining of BMP-2 was similar in the statin implanted group. Many   
Positive immunostaining cells were found at 1 week (Fig. 4A). But the positive stained 
cells decreased gradually at 2 weeks (Fig 4 B) and were at the minimum at 4 weeks (Fig. 
4C).  
ACS alone with BMP-2 antibody and Control with BMP-2 antibody 
Moreover there were very few positive stain cells in the ACS and control groups at early 
period (Figs 5A and B). 
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 Furthermore, we performed fluorescent double-immunostaining to compare the 
localization of the BMP-2 positive cells and Ki-67, a differentiating cell marker in the 4 
weeks of both implanted groups. The BMP-2 positive cells were partially overlapped 
with the Ki-67 marker especially in the statin implanted area (Fig6 A, B, C) and 
similarly showed positive immunoreactivity as in the rh-BMP-2 implanted group (Fig 7 
A, B, C).  
 
Statistical analysis 
For BMP-2 antibody, these time-course changes showed statistically significant 
differences by ANOVA (between subjects; F=122.287, df=2, P<0.0001; within subjects; 
F=29.237, df=6, P<0.0001).  In the group treated with BMP-2 antibody, there were no 
significant differences detected at any period between statin/ACS and rhBMP-2/ACS.  
Similarly, when ACS was compared with the control there were no significant 
differences detected at any period. However, when statin/ACS was compared with ACS 
and the control group, the cell numbers were found to be significantly increased in all 
periods (P<0.0001).  Similarly, when rhBMP-2/ACS was compared with ACS alone 
and the control group, the cell numbers were found to be significantly increased at all 
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       In this study we evaluated the bone regeneration process using two different 
implant factors and we compared the bone regenerative capability of these factors 
histologically and immunohistochemically in an animal model.  In this study, ACS of 
the same size were used as carriers in all groups except in the control group to make the 
same amount of space available for bone regeneration using the different implant factors.
 HMG-CoA reductase is one of the rate-limiting enzymes within the mevalonate 
pathway, through which cholesterol is biosynthesized.  This enzyme is effectively 
inhibited by statins causing a reduction in blood-cholesterol levels. Other products of 
the mevalonate pathway are also important for the prenylation of some kinds of small 
GTPases.  Since prenylated small GTPases are important for both activating 
osteoclasts and inhibiting the synthesis of BMP-2, statins inhibit the prenylation of 
small GTPases and, as a result, they can increase bone mass systemically10. 
In this study a new formulation of pravastatin/ACS material was used.  The 
materials were dispersed in a water solution, which made them suitable for injection and 
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the injection was applied in a critical bone defect to evaluate the process of bone 
regeneration.  Mundy et al.5 first reported that statins stimulated bone formation in 
rodents in vivo and that they increased the volume of new bone in cultures from mouse 
calvarium.  The enhancement of bone formation by statins is associated with an 
increase in the expression of BMP-2 through the activation of the gene promoter.  
 Wong et al. 11 reported that a pro-drug statin (Zocor®) can be dissolved in 
water and can induce the expression of BMP in surrounding tissues directly, and they 
found that following implantation of simvastatin, new bone was observed at 5 days 
post-operatively.  However, there have been no reports about the induction of bone 
formation by pravastatin in an in vivo model.  In this study, there were no findings to 
suggest the induction of inflammation in any of the specimens at 1 week 
post-operatively.  Osteoblasts and fibroblasts were clearly observed at 4 weeks 
post-operatively, but the formation of new bone was not clearly observed at our study, 
because of the short time period for observation. 
Osteogenesis induced by osteoblastic cells, is characterized by sequential 
events involving cell proliferation, followed by the expression of markers of the 
osteoblast phenotype and the synthesis, deposition, and mineralization of a collagenous 
matrix12, 13 Bone formation depends mainly on the number of osteoblastic cells rather 
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than the activity of the osteoblasts14.  The recruitment of osteoblastic cells plays a 
crucial role in osteogenesis.  This suggests that new bone formation might be seen over 
a longer post-operative time period that in the current study. 
Within subperiosteal implantation sites, BMP induces new bone formation in 
heterotrophic, intramuscular and orthotropic sites in vivo15.  It is thought that BMP 
induces the differentiation of pre-vascular mesenchymal connective tissue cells into 
bone and cartilage.  Various preparations of BMP have been reported to initiate new 
bone formation when implanted in animals7, 8, 16-18 but there have been no reports on the 
use of BMP in the nasal region.  In a previous study, a mesh-like woven bone structure 
was predominantly formed around the implant at 8 weeks post-implantation which 
diminished gradually16.  In the present study where BMP-2 was implanted, new bone 
was not observed clearly, but cells associated with connective tissues, including 
fibroblasts were observed. 
 
BMPs may initiate all of the molecular mechanisms required for the induction 
of bone formation, including the orderly migration, proliferation, and differentiation of 
osteoprogenitors, and the differentiation of mesenchymal cells into functional 
osteoblasts.  The formation of new bone by bone-inductive proteins depends on the 
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quantity of the BMPs available and the delivery system or carrier used.  Several 
carriers with suitable characteristics have been developed 7, 8, 17-19.  An ideal carrier 
should not only be resorbed and nonimmunogenic, but it should also provide a 
three-dimensional structure as a scaffold for new bone formation.  Polylactic 
acid/polyglycolic acid (PLGA) gelatin sponge (PGS) and collagen are considered to be 
suitable as carrier matrices for BMP and appear to facilitate the effects of BMP.  A 
BMP carrier should be nontoxic, biodegradable and conveniently sterilizable20.  ACS 
appears to be particularly promising as a biomaterial for the transport of BMP17, 19, 21.  
In the present study, most of the ACS could not be seen at 4 weeks post-implantation.  
Inoda et al.18 reported that following implantation of rhBMP-2 with collagen in the rat 
cervical model, most of the collagen had disappeared 6 weeks after implantation, and 
that all of the atelopeptide type 1 collagen sponge had been reabsorbed and substituted 
by mature bone 9 weeks after implantation.  
We have reported previously16 that newly formed bone observed at 8 weeks 
after implantation of doses of 5μg rh-BMP-2.  In other studies, it has been proved that 
lower doses than 5μg rh-BMP-2 could induce new bone7, 22, 23. It was considered that 
rabbits are significantly more sensitive to lower doses of rh-BMP-2, so that the dose of 
rh-BMP-2 used in this study was adequate and enough to induce new bone formation. 
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However, recently Herford and Boyne 24 have reported that the doses 1.5mg/ml 
rh-BMP-2which was clinically used to induce bone in patients. When clinical dose is 
considered, higher dose may be needed to obtain significant bone formation.   
On the other hand, there was no report regarding local use of pravastatin, so 
that it could be difficult to find the optimal dose of pravastatin.  Wang et al, 11 reported 
previously that the newly formed bone observed after implantation of the doses 10mg 
simvastatin in rabbit bone defect. This dose was equivalent as a tablet in the oral 
administration for human.  In the present study we used the doses 10mg of pravastatin 
in rabbit bone defect. This dose was equivalent as a tablet in the oral administration for 
human. Therefore, it was considered that the dose of pravastatin used in this study was 
enough to show the effect in rabbit bone defect. Furthermore, we tried to perform a 
preliminary study. From the results, when 10mg of pravastatin was used, osteoblast cell 
was shown significantly. On the basis of this result, we decided that the use of 10 mg of 
pravastatin was enough to induce new bone formation. However, further study is 
necessary to examine the effectiveness of various doses ranges of administration in or 
both rh-BMP-2 and statin in human.  
 
A variety of markers, including Ki67, proliferating cell nuclear antigen 
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(PCNA) and estrogen receptors are frequently used to study cellular proliferation.  In 
this study, we used the cell proliferation marker Ki67 which is expressed by 
proliferating cells in the late G1, S, and G2/M phases of the cell cycle.  The nuclear 
localization of Ki67 and its particular association with the cell cycle indicates its 
importance in the regulation of cell division.  Therefore, Ki67 has become an 
important marker of proliferating cells.  Our immunofluorescence studies 
demonstrated that BMP-2 was co-localized with Ki67 in most areas, and that similar 
levels of expression were observed for both the statin/ACS and rhBMP-2/ACS 
implanted sites. 
 From the results of the ANOVA analysis, the change in expression of BMP-2 
over time showed significant differences when the two implanted groups were 
compared with the control group (P < 0.0001).  Furthermore, when the data of the 
multiple comparison analysis with Scheffe’s F test at each period were added, our 
statistical analysis suggested that BMP-2 was expressed more intensely in both groups 
at 1 week post-operatively than it was at the other post-operative periods.  However, 
the sample number in each post-operative period was so small and the data so variable 
that the significant differences obtained with Scheffe’s F test could not be considered to 
be accurate.  Therefore, further examination using a larger sample number is required. 
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These immunohistochemical studies demonstrated that BMP-2 was strongly 
expressed in the connective tissue and periosteum following the implantation of the 
statin and rhBMP-2 in the rabbit nasal bone.  In addition, BMP-2 expression was 
similar in the sites implanted with statin or rhBMP-2 at every week that tissues were 
examined postoperatively.  We conclude that statin/ACS showed BMP-2 expression 
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FIGURE 1.  Intra-operative finding. (A) Bone defect was made at the nasal region. (B 
Diagram of the superior view of rabbit skull. Showing the sites of 4 surgically –created 
bone defects (a) Statin, (b) r-hBMP2, (c) atelo-collagen sponge, and (d) Control-no 
material were implanted within the defects. 
 
FIGURE 2. The frontal section of the nasal region with implanted materials. The 
yellow colored rectangle area indicates the area of observation. Arrows show the area 
of implanted material. B: bone, S: nasal septum, N: nasal cavity. 
 
FIGURE 3. Photomicrographs of statin/atelo-sponge group. Stained with BMP-2 
antibody at 1 week (A), 2 weeks (B) and 4 weeks (C.) (Immunohistochemical staining, 
original magnification ×100), P: positive stained cell. 
 
FIGURE 4. Photomicrographs of rhBMP-2/atelo-collagen sponge group. Stained with 
BMP-2 antibody at 1 week (A), 2 weeks (B) and 4 weeks(C). (Immunohistochemical 
staining, original magnification ×100), P: positive stained cell. 
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 FIGURE 5. Photomicrographs of the control and and atelo- collagen sponge group. 
Control Stained with BMP-2 antibody at 1 week(A) and atelo- collagen sponge stained 
with BMP-2 antibody at 1 week(B) (Immunohistochemical staining, original 
magnification ×100), P: positive cell area. 
 
FIGURE 6. Photomicrographs of immunofluorescence (IMF) BMP-2 and Ki 67 
expression in the statin implanted site. (A) BMP-2, (B) Ki67 (C) BMP-2 and Ki67 
co-localized area.  Ep: Epithelial tissue of the nasal membrane, B: Bone, N: Nasal 
cavity,    CT: Connective tissue.       
   
FIGURE7. Photomicrographs of immunofluorescence (IMF) BMP-2 and Ki 67 
expression in the rh-BMP-2 implanted site. (A) BMP-2, (B) Ki67, (C) BMP-2 and Ki67 
co-localized area. Ep: Epithelial tissue of the nasal membrane, B: Bone, N: Nasal Cavity, 
CT: Connective Tissue.     
 
FIGURE 8. The ratio of BMP-2 positive cells. The time-course changes in all the 
groups showed significant differences with ANOVA. 
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 Table 1. Results of the statistical analysis with Scheffe’s F test. Expression of positive 
stained cells with BMP-2 antibody.  























































































BMP2   antibody 1week 2weeks 4weeks
BMP2/ACS vs Control <0.0001 S <0.0001 S <0.0001 S
BMP2/ACS vs ACS <0.0001 S <0.0001 S <0.0001 S
BMP2/ACS vs Stain/ACS 0.430 NS 0.451 NS 0.956 NS
Control vs ACS 0.555 NS 0.870 NS 0.994 NS
Control vs Statin/ACS <0.0001 S <0.0001 S <0.0001 S
ACS vs Stain/ACS <0.0001 S <0.0001 S <0.0001 S
FIGURE 9
